Acemannan (Carravet)

Acemannan, marketed under the brand name Carravet, is a biologically derived wound healing product used in equine medicine to enhance tissue repair and accelerate wound healing. This complex polysaccharide is extracted from the inner leaf gel of the Aloe vera plant and has been purified and concentrated for medical use. Unlike simple aloe vera preparations, acemannan represents a specific active component that has demonstrated immunomodulatory and wound healing properties in scientific studies. The product is USDA-licensed for veterinary use and represents an evidence-based approach to wound healing enhancement in horses.

The mechanism of action of acemannan involves multiple pathways that collectively support and accelerate the wound healing process. As an immunomodulator, acemannan activates macrophages, the immune cells responsible for cleaning wounds and initiating tissue repair. Activated macrophages release growth factors including interleukins and tumor necrosis factor that stimulate fibroblast proliferation and collagen synthesis. Acemannan also enhances angiogenesis (new blood vessel formation) in wound beds, improving oxygen and nutrient delivery to healing tissues. Additionally, the hydrogel properties of acemannan formulations maintain optimal wound moisture levels that support cellular migration and tissue regeneration.

Acemannan is available as Carravet in freeze-dried gel and hydrogel formulations designed for direct wound application. The freeze-dried form is reconstituted before use and applied to wound surfaces where it forms a protective, bioactive layer. The hydrogel formulation provides ready-to-use convenience with the same wound healing benefits. Either formulation can be used under bandages or on open wounds depending on wound location and veterinary recommendations. Application is typically performed every two to three days, though frequency may vary based on wound characteristics and healing progress.

As a prescription veterinary product, acemannan requires authorization from a licensed veterinarian for use. The medication is typically reserved for wounds that are healing slowly, chronic non-healing wounds, or cases where enhanced healing is particularly important such as show or performance horses needing rapid return to activity. Veterinary evaluation ensures appropriate case selection and proper treatment protocols. While acemannan can significantly improve healing outcomes in suitable cases, it is not a substitute for proper wound care fundamentals including cleaning, infection control, and appropriate wound management.

The primary indication for acemannan in equine medicine is the enhancement of wound healing in cases where normal healing is delayed, compromised, or where accelerated healing is clinically desirable. This medication is particularly valuable for chronic wounds that have stalled in the healing process and are not progressing despite standard wound care. Wounds that remain open beyond expected healing timeframes, those with poor granulation tissue quality, or wounds showing minimal epithelialization over time are candidates for acemannan therapy. The immunomodulatory and growth-promoting effects of acemannan can help restart stalled healing processes.

Surgical wound healing enhancement represents an important use for acemannan. Post-operative wound care with acemannan can accelerate healing of surgical incisions and surgical wound sites, potentially reducing time to full recovery. This application is particularly valuable for surgical sites in locations prone to tension, movement, or contamination that might otherwise delay healing. Veterinarians may recommend acemannan following orthopedic procedures, tumor removals, reconstructive surgeries, or any surgical intervention where optimal healing is critical.

Degloving injuries and other traumatic wounds with significant tissue loss benefit from acemannan's wound healing properties. These severe injuries involving avulsion of skin and sometimes deeper tissues create wounds that heal slowly due to the extent of tissue damage. Acemannan's ability to stimulate granulation tissue formation and angiogenesis helps fill wound defects and prepare wound beds for epithelialization or skin grafting. The enhanced blood vessel formation improves tissue oxygenation and nutrient delivery critical for healing large tissue defects.

Proud flesh (exuberant granulation tissue) management is another application where acemannan has shown benefit. While acemannan promotes appropriate granulation tissue formation, it appears to support more normal wound healing rather than contributing to excessive tissue proliferation. Used as part of a comprehensive proud flesh treatment protocol, acemannan may help wounds transition from the granulation phase to epithelialization more effectively. The medication is often combined with other modalities addressing proud flesh when this complication develops.

Lower limb wounds in horses, which are notorious for slow healing and proud flesh formation, represent prime candidates for acemannan therapy. The distal extremities have limited blood supply and are subject to motion and contamination that impair healing. Acemannan's pro-angiogenic effects are particularly beneficial in these poorly vascularized areas. Pastern, fetlock, and cannon bone wounds that are healing slowly often show improved progress when acemannan is incorporated into the treatment regimen.

Acemannan administration begins with appropriate wound preparation to maximize the medication's effectiveness. The wound should be thoroughly cleaned to remove debris, necrotic tissue, and any barriers that would prevent acemannan from contacting viable tissue. Sterile saline irrigation is commonly used for wound cleaning. Necrotic or devitalized tissue should be debrided as needed, either surgically or through other debridement methods, before acemannan application. Clean, debrided wounds respond best to acemannan therapy because the medication can directly contact the tissues it needs to stimulate.

For freeze-dried acemannan (Carravet), the product is reconstituted according to manufacturer instructions before application. The reconstituted gel is then applied directly to the wound surface in a layer sufficient to cover all wound tissue. The gel should fill wound cavities and contact all wound surfaces requiring treatment. Once applied, the acemannan can be covered with a non-adherent dressing and appropriate bandaging materials if bandaging is indicated. For wounds treated open, the gel forms a protective layer over the wound surface.

The hydrogel formulation of acemannan is ready to use without reconstitution. The gel is applied directly from the container onto clean wound surfaces using sterile technique. Similar to the freeze-dried form, complete wound coverage ensures all areas receive the wound healing benefits. The hydrogel formulation may be preferred for convenience in clinical settings where multiple wound treatments are performed.

Application frequency for acemannan is typically every two to three days, though this may be adjusted based on wound characteristics and veterinary recommendations. More frequent application is generally unnecessary as the medication's effects persist between applications. Each application involves cleaning the wound, removing previous product residue, and applying fresh acemannan. The interval between applications allows time for the biological effects to occur while ensuring continued product presence in the wound.

Treatment duration with acemannan continues until satisfactory wound healing is achieved. For chronic wounds, significant improvement may be seen within two to four weeks of initiating therapy, though complete healing may require longer treatment courses. The veterinarian monitors healing progress and determines when acemannan therapy can be discontinued. Once wounds have adequately granulated and epithelialization is progressing well, transition to standard wound care may be appropriate. Premature discontinuation may allow healing to stall again, while continuing beyond clinical need offers diminishing benefit.

Combination therapy with acemannan and other wound care modalities is common. The medication can be used alongside systemic or topical antibiotics when infection is present or threatened. Acemannan does not possess inherent antimicrobial activity, so concurrent infection control measures are important. The product can also be incorporated into treatment protocols including hyperbaric oxygen therapy, therapeutic laser, or other advanced wound care techniques under veterinary direction.

Acemannan has an excellent safety profile when used topically for wound care, with adverse effects being uncommon in clinical use. The medication is derived from aloe vera, a plant with a long history of safe topical use, and the purified acemannan component maintains this favorable safety record. Most horses tolerate acemannan application without any adverse reactions, making it a well-accepted option for wound healing enhancement.

Local reactions at the application site are the most likely potential side effects, though they occur infrequently. Some horses may exhibit mild sensitivity to acemannan, manifesting as redness or minor irritation around the wound margins. This reaction is generally mild and may resolve with continued use or may warrant product discontinuation if persistent. True allergic reactions to acemannan are rare but possible, potentially presenting as more pronounced swelling, irritation, or hives near the treatment site.

Wound-related issues that might be mistakenly attributed to acemannan include normal wound healing phenomena that can appear concerning. Increased wound drainage initially after starting acemannan may reflect enhanced wound cleaning by activated macrophages rather than worsening infection. Changes in granulation tissue appearance as healing progresses are expected during normal wound repair. Veterinary evaluation can help distinguish between true adverse effects and expected healing responses.

Systemic side effects from topical acemannan application are not expected due to the minimal systemic absorption of topically applied polysaccharides. The large molecular size of acemannan limits its ability to penetrate intact tissues and enter systemic circulation. This favorable pharmacokinetic profile contributes to the medication's excellent safety record. There are no reported systemic toxicities from topical acemannan use in horses.

Rare considerations include the theoretical possibility of enhanced inflammatory response in some wound types. Because acemannan activates macrophages and stimulates cytokine release, wounds with excessive inflammation might theoretically experience increased inflammatory response. In practice, this concern has not proven clinically significant, and acemannan is generally considered safe for most wound types. Veterinary evaluation of wound characteristics helps ensure appropriate case selection.

Contraindications for acemannan use in horses are limited, reflecting the medication's excellent safety profile. The primary contraindication is known hypersensitivity to acemannan, aloe vera, or any component of the product formulation. Horses that have experienced allergic reactions to aloe-containing products should not be treated with acemannan without careful consideration and possibly supervised test application. Signs of previous hypersensitivity to aloe products may include contact dermatitis, hives, or other allergic manifestations following exposure.

Actively infected wounds require concurrent antimicrobial therapy when acemannan is used. Acemannan does not possess significant antimicrobial properties and should not be relied upon for infection control. Using acemannan on infected wounds without appropriate antibiotic coverage could allow infection to persist or worsen while the underlying wound healing enhancement occurs. Veterinary evaluation determines whether wounds require antimicrobial therapy alongside acemannan treatment.

Wounds with significant necrotic tissue burden should undergo debridement before acemannan application. The medication works by stimulating viable tissue to heal more effectively; it cannot enhance healing of devitalized tissue. Applying acemannan to wounds with substantial necrosis without first removing dead tissue wastes the medication and delays appropriate wound management. Surgical or mechanical debridement prepares the wound bed for effective acemannan therapy.

Cancerous or suspected cancerous wounds represent a relative contraindication for acemannan use. The growth-promoting and angiogenic properties of acemannan that benefit normal wound healing could theoretically support tumor growth or spread. Wounds associated with known tumors, masses, or suspicious lesions should be evaluated by a veterinarian before acemannan use. Biopsy may be indicated for unusual wounds before initiating growth-promoting therapies.

Acemannan has minimal documented drug interactions, consistent with its topical application route and biological mechanism of action. The medication works through immune modulation and growth factor stimulation rather than traditional pharmacological pathways, limiting potential interactions with other medications. This favorable interaction profile allows acemannan to be incorporated into multimodal wound care protocols alongside other treatments.

Concurrent use of topical antibiotics with acemannan is common and generally compatible. Antibacterial agents including silver sulfadiazine, nitrofurazone, or triple antibiotic preparations can be applied with or alternating with acemannan when infection control is needed alongside wound healing enhancement. Some practitioners apply antibiotic products at one dressing change and acemannan at the next, while others layer the products. Veterinary guidance determines the optimal approach for individual wounds.

Topical antiseptics and wound cleansers should be used appropriately with acemannan. While wound cleaning before acemannan application is important, residual antiseptic solutions in the wound bed could potentially interfere with the biological activity of acemannan. Thorough rinsing with sterile saline after antiseptic use removes residual solutions before acemannan application. Harsh antiseptics that damage viable tissue should generally be avoided in wounds being treated with acemannan, as they could counteract the healing enhancement effects.

Systemic medications including antibiotics, anti-inflammatories, and other drugs do not have significant interactions with topically applied acemannan. Horses receiving systemic therapy for concurrent conditions can have acemannan used for wound care without concern for drug interactions. However, some systemic medications may affect wound healing independent of acemannan. Corticosteroids and some chemotherapy agents can impair wound healing, potentially reducing acemannan effectiveness. Veterinary coordination ensures that wound care expectations account for effects of concurrent medications.

Competition considerations for acemannan are generally favorable, as the medication is not typically a prohibited substance under most equine sport regulations. However, as with any medication used in competition horses, verification with the applicable governing body is recommended. Documentation of acemannan use should be maintained in the horse's medication records. Wound conditions requiring acemannan treatment may themselves affect competition eligibility, which should be discussed with the attending veterinarian.

Monitoring during acemannan treatment focuses on wound healing progress and assessment for any local adverse reactions. With each dressing change and product reapplication, the wound should be evaluated for signs of appropriate healing including granulation tissue quality, wound size reduction, and epithelialization progress. Photography can help document healing progression over time. Wounds not showing expected improvement despite acemannan therapy warrant veterinary reassessment to identify potential barriers to healing such as underlying infection, foreign material, or systemic factors affecting wound repair.

Special populations requiring consideration include immunocompromised horses where the immunomodulatory effects of acemannan might have altered effects. Horses with PPID (Cushing's disease) often have impaired wound healing and immune function; while acemannan may still benefit these patients, expectations should account for the underlying condition's effects on healing. Young foals can be treated with acemannan under veterinary supervision, with typical pediatric considerations for any wound care in neonates.

Competition horses receiving acemannan treatment should have medication use documented. While acemannan itself is not typically prohibited, competition eligibility should be verified with relevant governing bodies when wounds occur in horses expected to compete. FEI, USEF, and breed organization regulations may vary, and current rules should be consulted. Horses with wounds significant enough to require acemannan therapy should have their competition schedule evaluated relative to adequate healing time regardless of medication status.

Wound care fundamentals remain essential when using acemannan. The medication enhances wound healing but does not replace proper wound management including appropriate cleaning, debridement when needed, infection control, and protection from contamination. Bandaging decisions, environmental management, and attention to factors affecting healing such as nutrition and exercise restriction all contribute to optimal outcomes. Acemannan is one component of comprehensive wound care, not a standalone solution.

Long-term use of acemannan is generally safe for chronic wounds requiring extended treatment. Unlike some wound care products that may cause tissue toxicity with prolonged use, acemannan's biological mechanism allows continued application as needed without accumulating adverse effects. Treatment duration is determined by wound healing response rather than concerns about extended use. However, wounds requiring very prolonged treatment without adequate progress should be reassessed for underlying causes of healing failure.

Acemannan products require specific storage conditions to maintain biological activity and effectiveness. The freeze-dried formulation should be stored according to manufacturer specifications, typically at controlled room temperature or refrigerated depending on the specific product. Reconstituted freeze-dried product has limited stability and should be used within the timeframe specified in product instructions, usually within 24 hours if refrigerated. Unused reconstituted product should be discarded after this period to ensure potency.

The hydrogel formulation of acemannan generally requires refrigerated storage to maintain stability. Product labeling specifies exact storage requirements, which should be followed carefully. The medication should be protected from freezing, as freeze-thaw cycles can damage the hydrogel structure and potentially affect biological activity. During transport to barn locations, maintaining cool temperatures preserves product integrity.

Light protection may be recommended for acemannan products, as some biological preparations are light-sensitive. Keeping the product in its original container and storing in a dark location when not in use helps maintain stability. The distinctive packaging of veterinary acemannan products is designed to provide appropriate protection during normal storage.

Proper handling during application maintains sterility and prevents contamination. Using sterile technique when removing product from containers prevents introducing bacteria into the remaining product. For multi-use containers, clean applicators should be used for each application. Avoiding contamination of container openings with wound exudate maintains product sterility for subsequent uses.

Expiration dates should be strictly observed for acemannan products due to the biological nature of the medication. Unlike some chemical drugs that may retain partial activity beyond expiration, biological products may lose effectiveness more completely. Expired product should be properly disposed of and replaced with fresh medication. Veterinary clinics and pharmacies can advise on appropriate disposal methods for expired biological products.

Draft horse breeds including Clydesdales, Shires, Belgians, and Percherons frequently sustain lower limb wounds that may benefit from acemannan therapy. These breeds' characteristic feathering can complicate wound care, and the large body size means wounds may be proportionally extensive. Acemannan can be particularly valuable for enhancing healing in these challenging wounds. Adequate quantities should be available to treat larger wound surfaces in draft horses. The generally calm temperament of draft breeds facilitates the regular wound care and dressing changes required during acemannan treatment.

Thoroughbreds and other performance breeds often have wounds that benefit from acemannan's healing enhancement due to the importance of rapid return to training. Racing and performance Thoroughbreds sustaining wounds during training or competition may have accelerated healing timelines with acemannan therapy. The medication's ability to enhance healing without systemic drug exposure makes it attractive for performance horses subject to drug testing. Documentation of acemannan use supports compliance with racing and competition regulations.

Ponies and miniature horses can be treated with acemannan following standard protocols, with product amounts adjusted for wound size. Smaller breeds often have proportionally smaller wounds but may be predisposed to certain wound healing challenges. Miniature horses and ponies with metabolic syndrome may have impaired wound healing that acemannan can help address. The product is applied based on wound dimensions rather than body size, so treatment protocols are similar across size categories.

There are no documented breed-specific contraindications or altered responses to acemannan. The genetic conditions affecting Quarter Horses (HYPP, PSSM, MH) do not impact acemannan use or effectiveness. Arabian genetic conditions and Friesian health issues similarly do not create specific concerns for acemannan therapy. All breeds can potentially benefit from acemannan wound healing enhancement when appropriate clinical indications exist. The medication's biological mechanism of action appears consistent across breed types.

Aloe vera products in various formulations represent the most closely related alternatives to acemannan. While acemannan is a purified, standardized extract of the active aloe component, whole aloe vera gels and preparations contain acemannan along with other aloe constituents. These over-the-counter products are widely available and less expensive than pharmaceutical acemannan, though their acemannan content is variable and often lower than the prescription product. For minor wounds, commercial aloe preparations may provide adequate benefit, while serious or chronic wounds may warrant the consistent potency of pharmaceutical acemannan.

Other biological wound healing products provide alternatives or complementary options to acemannan. Medical-grade honey products including Manuka honey wound dressings offer antimicrobial properties along with wound healing benefits through different mechanisms than acemannan. Platelet-rich plasma (PRP) preparations, though requiring specialized equipment for preparation, provide growth factors that enhance wound healing. These biological options can sometimes be combined or used sequentially under veterinary direction for wounds requiring aggressive healing support.

Conventional wound care products including topical antibiotics and protective barriers serve different but complementary roles compared to acemannan. Silver sulfadiazine and nitrofurazone provide antimicrobial activity without the healing enhancement of acemannan. Hydrogel dressings maintain wound moisture but lack biological activity. Comprehensive wound care often combines acemannan's healing enhancement with antimicrobial products and appropriate physical wound protection. Your veterinarian can design wound care protocols incorporating acemannan alongside other products based on individual wound assessment and treatment goals.